论文部分内容阅读
乙基紫苏霉素的合成已由Wright在1976年所阐述,它是紫苏霉素的新的半合成衍生物。由于它对氨基糖苷抗生素耐药菌有活性,动物实验毒性低,因而,被人们选用来进行更深入的研究。近年来,在加拿大市场上已有出售,其商品名为Netromycin,并即将得到食品药物管理局(FDA)的批准和广泛地应用。在加拿大,乙基紫苏霉素已经批准用于治疗由大肠杆菌、变形杆菌、克雷白氏杆菌、肠细菌、柠檬酸菌和葡萄球菌等敏感菌所引起的感染(在美国还未得到批准)。此
The synthesis of ethyl muscarin has been described by Wright in 1976 as a new semisynthetic derivative of microrhinin. Because of its activity of aminoglycoside antibiotic-resistant bacteria, animal experiments, low toxicity, therefore, was chosen for further research. In recent years, it has been marketed in the Canadian market under the trade name Netromycin and will soon be approved and widely used by the Food and Drug Administration (FDA). In Canada, ethyl musximycin has been approved for the treatment of infections caused by susceptible strains such as E. coli, Proteus, Klebsiella, enteric bacteria, citrobacter and staphylococcus (not yet approved in the United States ). this